Literature DB >> 28238595

Pembrolizumab as second-line treatment for urothelial cancer.

Fiona Mitchell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28238595     DOI： 10.1016/S1470-2045(17)30156-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

Review 1.  Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.

Authors:  Vikram Narayan; Andreas Kahlmeyer; Philipp Dahm; Nicole Skoetz; Michael C Risk; Connie Bongiorno; Neil Patel; Eu Chang Hwang; Jae Hung Jung; Gerald Gartlehner; Frank Kunath
Journal:  Cochrane Database Syst Rev       Date:  2018-07-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.